Back to Journals » Lung Cancer: Targets and Therapy » Volume 9

Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation

Total article views   Abstract views HTML views PDF downloads Totals
3,930 Dovepress* 2,513 594+ 652 3,107
PubMed Central* 0 823 116 823
Totals 2,513 1,417 768 3,930
*Since 8 November 2018
+Since July 2016

View citations on PubMed Central and Google Scholar